Interleukin Genetics Inc

(NASDAQ:ILI)
  Sep 30, 2008 Jun 30, 2008 Mar 31, 2008 Dec 31, 2007
Operating revenue
Total Revenue 2,172 2,476 2,655 2,311
Operating Revenue 2,172 2,476 2,655 2,311
Adjustments To Revenue — — — —
Cost Of Sales 925 1,235 1,264 996
Cost Of Sales With Depreciation 1,000 1,306 1,336 1,096
Gross Operating Profit 1,247 1,241 1,391 1,316
Operating Expenses
Research And Development Expenses 933 709 813 682
Selling General And Administrative Expenses 1,562 1,806 2,083 1,547
Advertising Expenses — — — —
Operating Income Before Depreciation -1,249 -1,273 -1,506 -913
Operating Income -1,659 -1,676 -1,908 -1,429
Depreciation 410 403 402 627
Depreciation Unreconciled — — — —
Amortization — — — 111
Amortization Of Intangibles 335 332 330 415
Operating Income After Depreciation -1,659 -1,676 -1,908 -1,540
Non Operating Expenses
Interest Expense 50 19 12 54
Pre Tax Income -1,671 -1,666 -1,857 -1,497
Income Taxes -29 -0 19 4
Minority Interest — — — —
Income Before Income Taxes -1,671 -1,666 -1,857 -1,497
Net Income From Continuing Operations -1,642 -1,666 -1,875 -1,501
Net Income From Discontinued Operations — — — —
Net Income From Total Operations -1,642 -1,666 -1,875 -1,501
Non Recurring Events
Extraordinary Income Losses — — — —
Income From Cummulated Effect Of Accounting Changes — — — —
Income From Tax Loss Carryforward — — — —
Other Gains And Losses — — — —
Total Net Income -1,642 -1,666 -1,875 -1,501
Normalized Income -1,642 -1,666 -1,875 -1,501
NetIncome Available For Common -1,642 -1,666 -1,875 -1,501
Preferred Dividends — — — —
Excise Taxes — — — —